LRMR

Larimar Therapeutics, Inc.
CAPPED RATING

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc. (LRMR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.5
EV / EBITDA -0.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -38.1%
Price Return 12M -25.6%
Catalyst Signal 0.00
Market Cap $280.5M
TTM Revenue N/A
Price / Sales N/A
ROE -139.6%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C (2.2) C- (2.1) D (1.3) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) C (2.2) C (2.2) D (1.5) C+ (2.7) C (2.2)
2026-10-30 C+ (2.5) C (2.2) C (2.2) D+ (1.8) C+ (2.7) C (2.3)
2026-10-23 C+ (2.5) C- (2.1) C (2.2) D+ (1.8) C+ (2.6) C (2.2)
2026-10-16 C+ (2.5) C- (2.1) C (2.2) D+ (1.8) C+ (2.6) C (2.2)
Page 1 of 3